BioVie Management

Management criteria checks 3/4

BioVie's CEO is Cuong Viet Do, appointed in Apr 2021, has a tenure of 3.08 years. total yearly compensation is $2.34M, comprised of 26.4% salary and 73.6% bonuses, including company stock and options. directly owns 0.92% of the company’s shares, worth $245.44K. The average tenure of the management team and the board of directors is 3 years and 4.9 years respectively.

Key information

Cuong Viet Do

Chief executive officer

US$2.3m

Total compensation

CEO salary percentage	26.4%
CEO tenure	3.1yrs
CEO ownership	0.9%
Management average tenure	3yrs
Board average tenure	4.9yrs

Recent management updates

Recent updates

BioVie: Recent Data In Alzheimer's Suggests +100% Upside Potential Within A Year

Oct 14

BioVie: Possibly Setting Up For Success With Alzheimer's And Parkinson's Results Imminent

Sep 06

BioVie: Four Potential Catalysts Around The Corner

Jun 07

CEO Compensation Analysis

How has Cuong Viet Do's remuneration changed compared to BioVie's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-US$43m
Sep 30 2023	n/a	n/a	-US$51m
Jun 30 2023	US$2m	US$618k	-US$50m
Mar 31 2023	n/a	n/a	-US$49m
Dec 31 2022	n/a	n/a	-US$41m
Sep 30 2022	n/a	n/a	-US$31m
Jun 30 2022	US$5m	US$300k	-US$26m
Mar 31 2022	n/a	n/a	-US$150m
Dec 31 2021	n/a	n/a	-US$145m
Sep 30 2021	n/a	n/a	-US$143m
Jun 30 2021	US$2m	n/a	-US$184m

Compensation vs Market: Cuong Viet's total compensation ($USD2.34M) is above average for companies of similar size in the US market ($USD667.96K).

Compensation vs Earnings: Cuong Viet's compensation has been consistent with company performance over the past year.

CEO

Cuong Viet Do (57 yo)

3.1yrs

Tenure

US$2,337,668

Compensation

Mr. Cuong Viet Do, M.B.A, is Independent Director of Adagene Inc. from November 2022. He serves as the Founder and Chairman at M6P Therapeutics. Mr. Do serves as a Director at Seneca Therapeutics, Inc., si...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Cuong Viet Do	President	3.1yrs	US$2.34m	0.92% $ 245.4k
Joanne Kim	CFO, Treasurer & Corporate Secretary	5.6yrs	US$723.87k	0.080% $ 21.5k
Joseph Palumbo	Executive VP of R&D and Chief Medical Officer	2.5yrs	US$1.09m	0.014% $ 3.6k
Clarence Ahlem	Senior Vice President of Operations	less than a year	no data	0.068% $ 18.1k
Penelope Markham	Senior Vice President of Liver Disease Program	no data	no data	no data
Denise Smith	Senior Vice President of Manufacturing & Development	5.3yrs	no data	no data
Christopher Reading	Senior Vice President of Alzheimer's Disease Program	2.8yrs	no data	0.068% $ 18.1k
Sarah Hoit	Chief Social Impact Officer	no data	no data	no data

3.0yrs

Average Tenure

63yo

Average Age

Experienced Management: BIVI's management team is considered experienced (3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Cuong Viet Do	President	8yrs	US$2.34m	0.92% $ 245.4k
Richard Jay Berman	Independent Director	4.9yrs	US$266.70k	0.032% $ 8.5k
Steven Gorlin	Independent Director	3.9yrs	US$209.55k	0% $ 0
Sigmund Rogich	Independent Director	3.9yrs	US$223.30k	0% $ 0
Robert Hariri	Independent Director	3.9yrs	US$209.55k	0.062% $ 16.7k
James Lang	Independent Chairman	7.4yrs	US$266.70k	0.034% $ 9.0k
Michael Sherman	Independent Director	6.8yrs	US$304.50k	0.038% $ 10.1k

4.9yrs

Average Tenure

64yo

Average Age

Experienced Board: BIVI's board of directors are considered experienced (4.9 years average tenure).

BioVie Management

Management criteria checks 3/4

Key information

Recent management updates

Independent Director recently sold US$128k worth of stock

BioVie Inc., Annual General Meeting, Nov 08, 2023

Insufficient new directors

BioVie Inc., Annual General Meeting, Nov 09, 2022

Recent updates

BioVie Awards up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

BioVie Receives Notice of Delisting from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

BioVie Receives Notice of Delisting from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

BioVie Inc. Announces Pipeline Update and Near-Term Clinical Priorities

BioVie Inc. has completed a Follow-on Equity Offering in the amount of $21 million.

New major risk - Shareholder dilution

Block & Leviton LLP Files A Class Action Lawsuit Against BioVie Inc. and Certain of Its Executives, for Securities Fraud

Block & Leviton LLP Files A Class Action Lawsuit Against BioVie Inc. and Certain of Its Executives, for Securities Fraud

Independent Director recently sold US$128k worth of stock

New minor risk - Market cap size

BioVie Inc. Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer’s Disease

BioVie Inc. Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2023

New major risk - Share price stability

BioVie Announces Late-Breaking Abstract Presenting Clinical Safety Data from the Company's Ascites Phase 2 Trial Accepted for Presentation at AASLD - The Liver Meeting®? 2023

BioVie Inc., Annual General Meeting, Nov 08, 2023

Price target increased by 11% to US$11.50

Insufficient new directors

BioVie Inc. Presents Data for NE3107 At 2023 International Congress of Parkinson’s Disease and Movement Disorders

Biovie Inc. Announces Phase 3 Trial of Ne3107 in Alzheimer's Disease

BioVie Inc. to Present Data Showing How NE3107 Potentially Regulates DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease

Biovie Inc. Announces Additional Findings from Phase 2 Alzheimer’s Disease Trial: Ne3107 Appears to Impact Biomarkers of Aging-Related Disease States in Addition to Observed Reversal of Cognitive Decline in Dementia

BioVie Inc. Announces Positive Results for NE3107 in Parkinson’s and Alzheimer’s Phase 2 Trials

Biovie Inc. Phase 3 Trial Assessing Ne3107 in Alzheimer's Disease Has Fully Enrolled the Targeted 316 Patients

BioVie Inc. Phase 2 Trial Assessing Ne3107's Pro-Motoric Activity in Parkinson's Disease Is Fully Enrolled

BioVie: Recent Data In Alzheimer's Suggests +100% Upside Potential Within A Year

BioVie Inc., Annual General Meeting, Nov 09, 2022

BioVie Inc. Announces Topline Results from an Investigator-Sponsored Phase 2 Clinical Trial of NE3107 for the Treatment of Alzheimer’s Disease

BioVie: Possibly Setting Up For Success With Alzheimer's And Parkinson's Results Imminent

BioVie Inc. announced that it has received $6.000001 million in funding from Acuitas Group Holdings Llc

BioVie Inc. announced that it expects to receive $6.000001 million in funding from Acuitas Group Holdings Llc

BioVie Inc. announced that it expects to receive $6.000001 million in funding from Acuitas Group Holdings Llc

BioVie Announces Patent Issuance Covering Ascites Treatment with BIV201

BioVie: Four Potential Catalysts Around The Corner

BioVie Announces Treatment of First Patient in Phase 2 Clinical Trial of NE3107 for the Treatment of Parkinson’s Disease

BioVie Inc. Contemplates Bankruptcy

BioVie Inc. has completed a Follow-on Equity Offering in the amount of $20 million.

Biovie Announces First Patient Enrolled in Phase 3 Study of Ne3107 in Alzheimer’s Disease

BioVie Inc. Announces First Patient Enrolled in BIV201 Phase 2b Clinical Trial for Ascites

BioVie Inc. Contemplates Bankruptcy

BioVie Commences Patient Screening in Phase 2 Clinical Trial

BioVie Inc. has completed a Follow-on Equity Offering in the amount of $15.652 million.

BioVie Inc. Contemplates Bankruptcy

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age